Viking Therapeutics, Inc.

Viking Therapeutics is a clinical-stage biotech focused on metabolic and endocrine diseases, most notably VK2735 — its dual GLP-1/GIP agonist for obesity that is one of the leading clinical-stage competitors to Lilly's Zepbound and Novo Nordisk's Wegovy. The stock has been one of the best 2026 biotech performers, up 51% since June 10 on a mix of upcoming data catalysts and M&A speculation.

• The company is pre-revenue: Q1 revenue was $0 (as expected for a clinical-stage biotech), with a Q1 operating loss of $158M — the equity value is entirely on the future value of VK2735 and the pipeline.
• The valuation is entirely narrative and catalyst driven: analysts model $7M in FY revenue as VK2735 completes late-stage development — the market cap of $4.3B is priced on Phase 3 approval probability and peak-sales estimates.
• The Piper Sandler Overweight with a $71 price target and their call that Q3 VK2735 SC maintenance data is "underappreciated" is real analyst-side positive setup — bulls are betting on that data cut extending the run past the current $43 52-week high.
• The AbbVie M&A speculation is the second catalyst layer: sentiment references AbbVie explicitly looking at Viking (both are San Diego-based) as its primary obesity BD target — that's the ABBV-just-bought-Apogee logic extended, and it's a credible transaction thesis.

The July 29 Q2 earnings will confirm cash burn and any interim VK2735 update, but the real catalyst is the Q3 SC maintenance data plus any inbound M&A discussions — a positive data cut plus continued AbbVie interest extends the run toward $50+; a soft data readout would give back most of the recent gain, and the 23M+ short interest cuts both ways.